大行評級|高盛:下調比亞迪電子目標價至57.35港元 維持“買入”評級
高盛發表報吿指,比亞迪電子去年下半年毛利遜預期,但預期公司毛利將於未來數年在產品組合向組件邁進的帶動下復甦。考慮到去年下半年業績,該行下調2025至2027年淨利預測各18%、19%、 12%,主要是因為毛利較低及業務擴張所需的研發投資增加。較低的毛利反映2024年較高的折舊及員工股票獎勵計劃成本,以及汽車供應鏈持續的價格競爭。該行維持比亞迪電子“買入”評級,目標價由67.05港元降至57.35港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.